Johnson & Johnson stock schedules December 8 review: rises 0.31 percent pre-market
Published on 10/28/2026 at 07:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSReview date and healthcare operations
- Johnson & Johnson announced an Enterprise Business Review for December 8, 2026.
- The company’s 2026 healthcare operations cover Innovative Medicine and MedTech.
- Johnson & Johnson stock trades pre-market at EUR 240.70 at 7:36 a.m. CET at Lang & Schwarz on October 28, 2026, 0.31 percent above the Xetra close of October 27, 2026.
Johnson & Johnson stock is 0.31 percent above the Xetra close of October 27, 2026. At 7:36 a.m. CET on October 28, 2026, the stock traded pre-market at EUR 240.70 at Lang & Schwarz, versus the Xetra close of EUR 239.95. Separately, in a release dated October 27, 2026, Johnson & Johnson announced an Enterprise Business Review for December 8, 2026.
Enterprise review scheduled
The company said the event will include an enterprise overview from Chairman and Chief Executive Officer Joaquin Duato and a financial overview from Chief Financial Officer Joe Wolk. The program is scheduled to begin with a general session at 8:30 a.m. ET and conclude at approximately 3:45 p.m. ET. Presentations will cover the Innovative Medicine and MedTech businesses, along with pipeline developments and long-term strategy, according to the company release.
Ahead of the Xetra open
The pre-market indication is EUR 0.75 above the Xetra close. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Johnson & Johnson stock.
Healthcare operations and the day
Johnson & Johnson operates through its Innovative Medicine and MedTech businesses, generating healthcare products and services in those markets. The December 8, 2026 review is the next company date identified in the release, with management presentations and question-and-answer sessions on the agenda. Market context: Market report S&P 500.
